Clicky

Simcere Pharmaceutical Group Ltd(2096)

Description: Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.


Keywords: Pharmaceutical Products Pharmacology Alzheimer's Disease Tablet Pharmacokinetics Capsule Pharmaceutical Manufacturers Simcere Pharmaceutical Diclofenac Orencia Amoxicillin Pharmacy Chains Abatacept Edaravone Diclofenac Sodium Modified Release Dosage

Home Page: www.simcere.com

No. 699-18, Xuanwu Road
Nanjing, 210042
China
Phone: 86 25 8556 6666


Officers

Name Title
Mr. Jinsheng Ren Co-Founder, Chairman & CEO
Mr. Renhong Tang Ph.D. Co-CEO & Exec. Director
Mr. Yushan Wan CFO, Joint Company Sec. & Exec. Director
Mr. Quanfu Feng VP of Marketing
Dr. Kevin Oliver Ph.D. Sr. VP
Dr. Bijoyesh Mookerjee M.D. Chief Medical Officer of Oncology
Mr. Danny Chen Ph.D. Senor VP
Andrew Zhu Sr. VP
Dr. Tamas Oravecz Ph.D. Sr. VP & Chief Scientific Officer of U.S.
Song Wenjie Sr. VP

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 22.1729
Trailing PE: 30.3556
Price-to-Book MRQ: 4.0973
Price-to-Sales TTM: 4.8255
IPO Date:
Fiscal Year End: December
Full Time Employees: 6542
Back to stocks